You just read:

KalVista Pharmaceuticals Raises $33 Million to Advance Development of Novel Plasma Kallikrein Inhibitors in Diabetic Macular Edema and Hereditary Angioedema

News provided by

KalVista Pharmaceuticals

Jul 22, 2015, 04:00 ET